Ignite Creation Date:
2024-05-06 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 12:40 PM
Study NCT ID:
NCT03431688
Status:
UNKNOWN
Last Update Posted:
2019-03-06
First Post:
2018-01-31
Brief Title:
Tailored Therapy for Clarithromycin-Resistant H Pylori
Sponsor:
Kangdong Sacred Heart Hospital
Organization:
Kangdong Sacred Heart Hospital
Study Overview
Official Title:
Efficacy Comparison of Metronidazole-based Triple and Bismuth-based Quadruple Therapy for Clarithromycin Resistant-Helicobacter Pylori Infection Randomized Controlled Trial
Status:
UNKNOWN
Status Verified Date:
2019-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clarithromycin-resistant H pylori is the main cause of H pylori eradication failure Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently however there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H pylori We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM proton pump inhibitor amoxicilline metronidazole regimen and PBMT proton pump inhibitor bismuth metronidazole tetracyclin regimen in patient with clarithromycin-resistant H pylori
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None